{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:03:29Z","timestamp":1780452209467,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clinthera.2024.06.014","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T11:08:31Z","timestamp":1722078511000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Physiologically Based Pharmacokinetic Model for Predicting Omadacycline Pharmacokinetics and Pharmacodynamics in Healthy and Hepatic Impairment Populations"],"prefix":"10.1016","volume":"46","author":[{"given":"Ailin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.06.014_bib0001","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2147\/IDR.S171352","article-title":"Omadacycline: a novel aminomethylcycline","volume":"12","author":"Burgos","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0002","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jama.2019.8199","article-title":"Omadacycline (Nuzyra) - a new tetracycline antibiotic","volume":"322","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0003","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2217\/fmb-2020-0182","article-title":"Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"15","author":"Chopra","year":"2020","journal-title":"Future Microbiol"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40261-022-01119-9","article-title":"Omadacycline oral dosing and pharmacokinetics in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection","volume":"42","author":"Leviton","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","article-title":"Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics","volume":"59","author":"Rodvold","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0008","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","article-title":"Omadacycline: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0009","doi-asserted-by":"crossref","first-page":"e01650","DOI":"10.1128\/AAC.01650-20","article-title":"An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of omadacycline","volume":"64","author":"Kovacs","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0010","article-title":"Pharmacokinetics, safety and pharmacokinetics\/pharmacodynamics analysis of omadacycline in Chinese healthy subjects","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0011","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","article-title":"Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects","volume":"60","author":"Sun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0012","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/DDDT.S297981","article-title":"Development and evaluation of a physiologically based pharmacokinetic drug-disease model of propranolol for suggesting model informed dosing in liver cirrhosis patients","volume":"15","author":"Kalam","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0013","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cpt.2445","article-title":"Whole body PBPK modeling of remdesivir and its metabolites to aid in estimating active metabolite exposure in the lung and liver in patients with organ dysfunction","volume":"111","author":"Fan","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0016","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and preclinical review of omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0017","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC202204190","article-title":"Community-acquired pneumonia","volume":"175","author":"Rothberg","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14787210.2023.2174100","article-title":"Omadacycline in treating community-based infections: a review and expert perspective","volume":"21","author":"Sakoulas","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02213-21","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia arising from Streptococcus pneumoniae and Haemophilus influenzae","volume":"67","author":"Bhavnani","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0020","first-page":"e01784","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0021","doi-asserted-by":"crossref","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0022","doi-asserted-by":"crossref","first-page":"e02368","DOI":"10.1128\/AAC.02368-16","article-title":"In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0023","doi-asserted-by":"crossref","first-page":"e02265","DOI":"10.1128\/AAC.02265-19","article-title":"Pharmacokinetic-pharmacodynamic characterization of omadacycline against Haemophilus influenzae using a one-compartment in vitro infection model","volume":"64","author":"VanScoy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0024","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.01478-13","article-title":"Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients","volume":"58","author":"Zvada","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0025","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0026","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0027","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0028","doi-asserted-by":"crossref","first-page":"e02327","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.06.014_bib0029","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii","volume":"76","author":"Noel","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:30:18Z","timestamp":1724949018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824001899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0149291824001899"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Model for Predicting Omadacycline Pharmacokinetics and Pharmacodynamics in Healthy and Hepatic Impairment Populations","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}